REFERENCES
- Janovic J, Brin M F. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–1193
- Botox Product Information. Allergan, Inc., Irvine, CA 1995
- Montecucco C, Giampietro S. Mechanism of action of tetanus and botulinum neurotoxins. Molecular Microbiology 1994; 13(1)1–8
- Hughes A J. Botulinum toxin in clinical practice. Drugs 1994; 48(6)888–893
- NIH Consensus Development Conference Statement. Clinical use of botulinum toxin. Arch Neurol 1991; 48: 1294–1298
- Acquadro M A, Borodic G E. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994; 80(3)705–706
- Cheshire W P, Abashian S W, Mann J D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59: 65–69
- Wheeler A H, Goolkasian P. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998; 23(15)1662–1667
- Wheeler A H. Botulinum Toxin A, Adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998; 38: 468–471
- AAN Meeting. Botox Promising As Migraine Treatment, www.pslgroup.com
- LeWitt P A, Trosch R M. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Movement Disorders 1997; 12(6)1064–1067
- American Academy of Neurology. Training Guidelines for the Use of Botulinum Toxin for the Treatment of Neurologic Disorders. Neurology 1994; 44: 2401–2403
- Drug Topics Red Book. Medical Economics. Inc. Montvale, NJ 1999